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We report two cases of infection with clonally unrelat-
ed, high-level ciprofloxacin-resistant, β-lactamase–produc-
ing strains of Salmonella enterica Typhimurium. Resistance
was caused by four topoisomerase mutations, in GyrA,
GyrB, and ParC and increased drug efflux. Ciprofloxacin
treatment failed in one case. In the second case, reduced
susceptibility to third-generation cephalosporins occurred
after initial treatment with these drugs and may explain the
treatment failure with ceftriaxone. 
C
iprofloxacin, a member of the large and widely used
fluoroquinolone group of antimicrobial drugs, is con-
sidered the empirical treatment of choice of gastrointestinal
infections in adults. The fluoroquinolones have been
licensed for use in humans as well as in food-producing ani-
mals. This use has raised a worldwide debate on the selec-
tion of fluoroquinolone-resistant bacteria in, and the possi-
ble circulation between, the different ecosystems concerned
(1). While resistance to these drugs occurred quickly in
Escherichia coli and several other enterobacteriaceae, high-
level resistance to ciprofloxacin (HLRC) has been found
exceptionally in salmonellae (2–5). The low prevalence of
salmonellae with HLRC has been ascribed to counter selec-
tion in the environment (6), an observation corroborated by
the difficulty in selecting HLRC mutants in vitro. This type
of resistance generally involves multiple mutations in the
genes encoding the quinolone target enzymes, gyrase and
topoisomerase IV (2), and mutations in regulatory systems
(marORAB  [7]) or soxRS [8]) or drug efflux systems
(AcrAB) (9). We report two cases of infection caused by
multiple-resistant Salmonella enterica Typhimurium with
HLRC in which initial therapy failed and present data on the
fluoroquinolone resistance mechanism.
The Study
Case 1
A 74-year-old man with an aorto-femoral bypass and
chronic prostatitis became febrile and was treated empiri-
cally with ciprofloxacin. After 2 weeks of persistent fever,
he was hospitalized. Pyelonephritis was diagnosed and
endocarditis suspected. Urinalysis and blood culture both
led to the isolation of a strain of S. Typhimurium (STmA)
resistant to ciprofloxacin, amoxicillin, tetracycline, chlo-
ramphenicol, and sulfonamide. Treatment with cefo-
taxime was started, the fever subsided, and the patient
recovered and was discharged. He did not go for follow-
up consultations. 
Case 2
A 3-month-old boy (body weight 6 kg) arrived at the
hospital with severe diarrhea and fever. A stool culture
indicated a strain of S. Typhimurium (STmB1) resistant to
ciprofloxacin, amoxicillin, tetracycline, trimethoprime,
chloramphenicol, streptomycin, spectinomycin, and gen-
tamicin. Treatment was initiated with ceftriaxone IV (250
mg/day) and maintained for 7 days. Signs and symptoms
improved for a few days, but fever relapsed after 2 weeks.
A second stool culture indicated S. Typhimurium strain
STmB2, with the resistance phenotype of the original iso-
late. A second treatment with the same antimicrobial drug
IV (300 mg/day) was given for 6 days, again with apparent
initial success. However, fever and diarrhea reoccurred
after 3 weeks (isolation of strain STmB3 from stool sam-
ple). All symptoms disappeared after oral treatment with
cefpodoxime (96 mg/day/7 days). The search for carriers
within the family was positive in one, with isolation of
strain STmC in a 1-year-old sibling who showed no clini-
cal signs of infection.
All STm strains were analyzed for their lysotype,
pulsed-field gel electrophoretic (PFGE) pattern, and resist-
ance phenotype and genotype, as previously described
(10). Strain STmA was phage nonsusceptible; all STmB
and STmC strains were of lysotype 12. The last two had
identical PFGE profiles after digestion of genomic DNA
with XbaI, patterns that were clearly different from that of
STmA (5 of 12 fragments were in common). Polymerase
chain reaction (PCR) amplification indicated β-lactamase
genes in these strains of type TEM in STmA and of type
TEM and OXA-1 in the STmB and STmC strains. MICs of
the antimicrobial drugs shown in the Table were deter-
mined for the five clinical strains and the reference strain
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Mueller-Hinton medium containing serially twofold dilut-
ed antimicrobial drugs. MICs of ethidium bromide and of
ciprofloxacin, cefotaxime, and ceftriaxone in the presence
of the efflux pump inhibitor Phe-Arg-β-naphthylamide
(Sigma-Aldrich Chimie, Saint Quentin Fallavier, France)
(11) at concentrations of 50 mg/L were also determined.
All clinical strains were similarly high-level resistant to
fluoroquinolones. Isolate STmA, producing the TEM β-
lactamase, was more susceptible to cefotaxime and ceftri-
axone than the STmB and STmC isolates producing in
addition OXA-1, and the post-treatment STm strains B2
and B3 were two- to fourfold less susceptible to the third-
generation cephalosporins than STmB1 (Table). In the
presence of Phe-Arg-β-naphthylamide at 50 mg/L, a con-
centration at which no inhibition of growth was observed
in the controls, MICs of ciprofloxacin were reduced four-
fold and those of cefotaxime and ceftriaxone were reduced
twofold. All STm isolates showed strongly reduced sus-
ceptibility to ethidium bromide (MIC > 1,000 mg/L as
opposed to <100 mg/L for the reference strain).
To identify mutations responsible for HLRC, the
quinolone resistance determining regions (QRDR) of
DNA gyrase and topoisomerase IV were determined after
nucleotide sequencing of the corresponding QRDR frag-
ments which were PCR-amplified with the respective pairs
of primers: 5′CTGAAGCCGGTACACCGTCG and
5′TCGGCCATCAGTTCGTGGGC for gyrA; 5′TTATC-
GATGCTGCGCGTGCC and 5′TCGCCGCTTTCAG-
GGCGTTC for gyrB; 5′CGCCTACTTAAACTACTCCA
and 5′ATCAGCGTAATCGCCGCTTT for  parC; and
5′GACC-GAGCTGTTCCTTGTGG and 5′GCGTAACT-
GCATCGGGTTCA for parE. The QRDRs of the topoiso-
merases of the five strains had identical mutations in GyrA
(Ser83Phe and Asp87Asn) and in GyrB (Ser464Phe),
while distinct mutations were observed in ParC (Glu84Lys
in strain STmA and Ser80Arg in all STmB and STmC
strains). The recently described quinolone resistance-con-
ferring gene qnr was absent from all STm strains as tested
by PCR with the corresponding specific primers (12).
Also, nucleotide sequencing did not show any mutation in
the PCR-amplified marORA locus.
Electrophoretic (sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis) analysis of outer membrane
proteins indicated the loss of one of them, possibly a porin
(data not shown), in the post-treatment isolates STmB2
and STmB3. These changes did not influence the levels of
fluoroquinolone resistance but were associated with
reduced susceptibility to cefoxitin (not shown) and cefo-
taxime (fourfold) and to ceftriaxone (twofold) (Table). 
Conclusions 
The two cases reported here show that clonally unrelat-
ed HLRC strains of S. Typhimurium, which may cause
severe infections, are present in the community. In both
cases initial treatment failed, respectively, with a fluoro-
quinolone and a third-generation cephalosporin. In the first
case, the failure may be attributable to the multiple topoi-
somerase mutations (possibly in conjunction with
increased drug efflux), although treatment failures have
been reported in cases of lower levels of resistance to
ciprofloxacin (13). In the second case, the reason for the
initial treatment failure with ceftriaxone is less obvious.
Strain STmB1 had the potential to decrease its susceptibil-
ity to third-generation cephalosporins under treatment,
possibly related to the loss of an outer membrane protein.
The high-level resistance to ethidium bromide and the
increased susceptibility of the strains to ciprofloxacin in
the presence of Phe-Arg-β-naphthylamide were strongly
suggestive of an activated drug efflux system, such as
AcrAB, the substrates of which also include
cephalosporins with lipophilic side chains (2,14). The
growth rates of the strains were the same as that of the ref-
erence strain, an observation which is at variance with that
made with experimental fluoroquinolone-resistant mutants
selected in animals (6) and which might imply the exis-
tence of additional compensatory mutants in the human
STm isolates.
Low-level ciprofloxacin resistance in salmonellae has
been observed occasionally in the environment in France
(15) and elsewhere (16). Since we did not have a pretreat-
ment isolate at our disposal, we are not certain whether any
of the mutations resulting in the high-level fluoro-
quinolone resistance observed in strain STmAwere select-
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Table. Antimicrobial drug susceptibilities of the Salmonella enterica Typhimurium isolates  
MIC (mg/L)
a 
Isolate  NOR  CIP
b  CTM  CTX 
NCTC  12416  0.06  0.016  0.06  0.125 
A  32  16  0.06  0.06 
B1  32  32  0.25  0.125 
B2  32  32  1  0.25 
B3  32  32  1  0.25 
C  32  32  0.25  0.125 
aNOR, norfloxacin; CIP, ciprofloxacin; CTM, cefotaxime; CTX, ceftriaxone. 
bMICs of moxifloxacin were identical to those of CIP. ed under treatment. On the other hand, HLCR strain STmB
may have been acquired as such from the environment or
through the food chain, since neither the patient nor his
sibling had ever been treated with fluoroquinolones,
although no salmonellae with this phenotype have been
observed to date from environmental or animal sources in
France. In fact, to our knowledge, quadruple mutations
affecting three topoisomerase subunits have never been
reported before in salmonellae.
The unwelcome occurrence of fluoroquinolone-resist-
ant salmonellae accumulating multiple mechanisms of
resistance could compromise standard therapy of infec-
tions attributable to such pathogens. For children, an initial
high-dose regimen with commonly used third-generation
cephalosporins, or with oral cephalosporins, may therefore
be indicated for the treatment of infections caused by S.
Typhimurium strains such as STmB1.
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